横田伸一 Shin-ichi Yokota, MS, PhD
原著論文
1. Yokota S, Kaya S, Kawamura T, Araki Y, Ito E. The structure of the O-specific chain of lipopolysaccharide from Pseudomonas aeruginosa IID 1008 (ATCC 27584). J Biochem 1986;99(6): 1551-1561.
2. Yokota S, Kaya S, Sawada S, Kawamura T, Araki Y, Ito E. Characterization of a polysaccharide component of lipopolysaccharide from Pseudomonas aeruginosa IID 1008 (ATCC 27584) as D-rhamnan. Eur J Biochem 1987;167(2): 203-209.
3. Yokota S, Kaya S, Araki Y, Ito E. Structure of the O-polysaccharide chain of lipopolysaccharide from Pseudomonas aeruginosa IID 1001 (ATCC 27577). J Biochem 1988;104(4): 671-678.
4. Yokota S, Ochi H, Ohtsuka H, Kato M, Noguchi H. Heterogeneity of the L-rhamnose residue in the outer core of Pseudomonas aeruginosa lipopolysaccharide, characterized by using human monoclonal antibodies. Infect Immun 1989;57(6): 1691-1696.
5. Yokota S, Kaya S, Noguchi H. Antigenic epitope in Pseudomonas aeruginosa lipopolysaccharide immunologically cross-reactive with Escherichia coli O26 lipopolysaccharide. FEMS Microbiol Lett 1990;56(3): 245-248.
6. Yokota S, Ochi H, Uezumi I, Ohtsuka H, Irie K, Noguchi H. N-Acetyl-L-galactosaminuronic acid as an epitope common to the O-polysaccharides of Pseudomonas aeruginosa serotype A and H (Homma) recognized by a protective human monoclonal antibody. Eur J Biochem 1990;192(1): 109-113.
7. Yokota S, Kaya S, Araki Y, Ito E, Kawamura T, Sawada S. Occurrence of D-rhamnan as the common antigen reactive against monoclonal antibody E87 in Pseudomonas aeruginosa IFO 3080 and other strains. J Bacteriol 1990;172(10): 6162-6164.
8. Terashima M, Uezumi I, Tomio T, Kato M, Irie K, Okuda T, Yokota S, Noguchi H. A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide. Infect Immun 1991;59(1): 1-6.
9. Ochi H, Ohtsuka H, Yokota S, Uezumi I, Terashima M, Irie K, Noguchi H. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa. Infect Immun 1991;59(2): 550-554.
10. Yokota S, Terashima M, Chiba J, Noguchi H. Variable cross-reactivity of Pseudomonas aerginosa lipopolysaccharide-core-specific monoclonal antibodies and its possible relationship with serotype. J Gen Microbiol 1992;138(2): 289-296.
11. Ohtsuka H, Horigome K, Higuchi A, Nomura N, Ochi H, Yokota S, Kohzuki T, Noguchi H. Binding of monoclonal antibody specific for domain Ia/II of Pseudomonas aeruginosa exotoxin A at pH4 strongly neutralizes exotoxin A-induced cytotoxity in cell culture and in vivo. Infect Immun 1992;60(3): 1061-1068.
12. Yokota S, Ohtsuka H, Noguchi H. Monoclonal antibodies against Pseudomonas aeruginosa elastase: a neutralizing antibody which recognizes a conformational epitope related to an active site of elastase. Eur J Biochem 1992;206(2): 587-593.
13. Eguchi H, Kaya S, Araki Y, Kojima N, Yokota S. Structure of the O-polysaccharide chain of the lipopolysaccharide of Vibrio anguillarum V-123. Carbohydr Res 1992;231: 159-169.
14. Yokota S, Noguchi H. Epitopes for human monoclonal antibodies and serotyping antisera against the O-specific polysaccharide of Pseudomonas aeruginosa O11. Carbohydr Res 1994;261(1): 57-66.
15. Yokota S, Hayashi T, Matsumoto H. Identification of the lipopolysaccharide core region as the receptor site for a cytotoxin-converting phage, fCTX, of Pseudomonas aeruginosa. J Bacteriol 1994;176(17): 5262-5269.
16. Hayashi T, Matsumoto H, Ohnishi M, Yokota S, Shinomiya T, Kageyama M, Terawaki Y. Cytotoxin-converting phages, fCTX and PS21, are R pyocin-related phages. FEMS Microbiol Lett 1994;122(3): 239-244.
17. Ohno A, Ishii Y, Tateda K, Matumoto T, Miyazaki S, Yokota S, Yamaguchi K. Role of LPS length in clearance rate of bacteria from the bloodstream in mice. Microbiology 1995;141(10): 2749-2756.
18. Yokota S. Identification of outer membrane proteins as target antigens of Pseudomonas aeruginosa Homma serotype M. Clin Diagn Lab Immunol 1995;2(6): 747-752.
19. Yokota S, Nunn MF, Morooka S. Cross-linking of the ninth consensus repeat domain of P-selectin (GMP-140, CD62P) with a monoclonal antibody enhanced leukocyte adhesive activity. Biochem Biophys Res Commun 1996;218(3): 709-713.
20. Yokota S. Novel O-polysaccharide expression, as a lipid A-core-free form, in a lipopolysaccharide-core-defective mutant of Pseudomonas aeruginosa. Microbiology 1996;142(2): 289-297.
21. Yokota S, Ohtsuka H, Kohzuki T, Noguchi H. A polyreactive human anti-lipid A monoclonal antibody having cross reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides. FEMS Immunol Med Microbiol 1996;14(1): 31-38.
22. Tojo SJ, Yokota S, Koike H, Schultz J, Hamazume Y, Misugi E, Yamada K, Hayashi M, Paulson JC, Morooka S. Reduction of rat myocardial ischemia and reperfusion injury by sialyl Lewis X oligosaccharide and anti-rat P-selectin antibodies. Glycobiology 1996;6(4): 463-469.
23. Yokota S, Amano K, Hayashi S, Fujii N. Low antigenicity of the polysaccharide region of Helicobacter pylori lipopolysaccharides derived from tumors of patients with gastric cancer. Infect Immun 1997;65(9): 3509-3512.
24. Amano K, Hayashi S, Kubota T, Fujii N, Yokota S. Reactivities of Lewis antigen monoclonal antibodies with the lipopolysaccharides of Helicobacter pylori strains isolated from patients with gastroduodenal diseases in Japan. Clin Diagn Lab Immunol 1997;4(5): 540-544.
25. Yokota S, Amano K, Hayashi S, Kubota T, Fujii N, Yokochi T. Human antibody response to Helicobacter pylori lipopolysaccharide: presence of an immunodominant epitope in the polysaccharide chain of lipopolysaccharide. Infect Immun 1998;66(6): 3006-3011.
26. Amano K, Yokota S, Ishioka T, Hayashi S, Kubota T, Fujii N. Utilization of proteinase K-treated cells as lipopolysaccharide antigens for the serodiagnosis of Helicobacter pylori infections. Microbiol Immunol 1998;42(7): 509-514.
27. Kubota H, Yokota S, Yanagi H, Yura T. Structures and co-regulated expression of the genes encoding mouse cytosolic chaperonin CCT subunits. Eur J Biochem 1999;262(2): 492-500.
28. Isogai E, Isogai H, Amano K, Yokota S, Hayashi S, Hirose K, Oguma K, Hirai Y, Asaka M, Sugiyama T. Effect of Helicobacter pylori lipopolysaccharides on human polymorphonuclear neutrophils and endothelial cells. Biosci Microflora 1999;18(2): 119-124.
29. Kubota H, Matsumoto S, Yokota S, Yanagi H, Yura T. Transcriptional activation of mouse cytosolic chaperonin CCT subunit genes by heat shock factors HSF1 and HSF2. FEBS Lett 1999;461(1/2): 125-129.
30. Yokota S, Yanagi H, Yura T, Kubota H. Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G1/S transition through early S phase. J Biol Chem 1999;274(52): 37070-37078.
31. Yokota S, Amano K, Shibata Y, Nakajima M, Suzuki M, Hayashi S, Fujii N, Yokochi T. Two distinct antigenic types of the polysaccharide chains of Helicobacter pylori lipopolysaccharides characterized by reactivity with sera from humans with natural infection. Infect Immun 2000;68(1): 151-159.
32. Yokota S, Yangi H, Yura T, Kubota T. Upregulation of cytosolic chaperoning CCT subunits during recovery from chemical stress that causes accumulation of unfolded proteins. Eur J Biochem 2000;267(6): 1658-1664.
33. Yokota S, Amano K, Fujii N, Yokochi T. Comparison of serum antibody titers to Helicobacter pylori lipopolysaccharides, CagA, VacA and partially purified cellular extracts in a Japanese population. FEMS Microbiol Lett 2000;185(2): 193-198.
34. Monteiro MA, Zheng P, Ho B, Yokota S, Amano K, Pan Z, Berg DE, Chan KH, MacLean LL, Perry MB. Expression of histo-blood group antigens by lipopolysaccharides of Helicobacter pylori strains from Asian hosts: the propensity to express type 1 blood-group antigens. Glycobiology 2000;10(7): 701-713.
35. Kubota H, Yokota S, Yanagi H, Yura T. Transcriptional regulation of the mouse cytosolic chaperonin subunit gene Ccta/t-complex polypeptide 1 by selenocysteine tRNA gene transcription activating factor family zinc finger proteins. J Biol Chem 2000;275(37): 28641-28648.
36. Yokota S, Hirata D, Minota S, Higashiyama T, Kurimoto M, Yanagi H, Yura T, Kubota H. Autoantibodies against chaperonin CCT in human sera with rheumatic autoimmune diseases: comparison with antibodies against other Hsp60 family proteins. Cell Stress Chaperones 2000;5(4): 337-346.
37. Yokota S, Kayano T, Ohta T, Kurimoto M, Yanagi H, Yura T, Kubota H. Proteasome-dependent degradation of cytosolic chaperonin CCT. Biochem Biophys Res Commun 2000;279(2): 712-717.
38. Kubota T, Yokosawa N, Yokota S, Fujii N. C terminal CYS-RICH region of mumps virus structural V protein correlates with block of interferon a and g sign transduction pathway through decrease of STAT 1- a. Biochem Biophys Res Commun 2001;283(1): 255-259.
39. Yokota S, Yokosawa N, Kubota T, Suzutani T, Yoshida I, Miura S, Jimbow K, Fujii N. Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and Janus kinases during an early infection stage. Virology 2001;286(1): 119-124.
40. Yokota S, Yanagi H, Yura T, Kubota H. Cytosolic chaperonin-containing t-complex polypeptide 1 changes the content of a particular subunit species concomitant with substrate binding and folding activities during the cell cycle. Eur J Biochem 2001;268(17): 4664-4673.
41. Yokota S, Yamamoto Y, Shimizu K, Momoi H, Kawakami T, Yanagi H, Yura T, Kubota H. Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma. Cell Stress Chaperones 2001;6(4): 345-350.
42. Yokota S, Sato K, Kuwahara O, Habadera S, Tsukamoto N, Ohuchi H, Akizawa H, Himi T, Fujii N. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 2002;46(10): 3311-3315.
43. Kubota T, Yokosawa N, Yokota S, Fujii. N. Association of mumps virus V protein with RACK1 results in dissociation of STAT-1 from the alpha interferon receptor complex. J Virol 2002;76(24): 12676-12682.
44. Yokosawa N, Yokota S, Kubota T, Fujii N. C-Terminal region of STAT-1 a is not necessary for its ubiquitination and degradation caused by mumps virus V protein. J Virol 2002;76(24): 12683-12690.
45. Yokota S, Saito H, Kubota T, Yokosawa T, Amano K, Fujii N. Measles virus suppresses interferon- a signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-a receptor complex. Virology 2003;306(1): 135-146.
46. Yonekura N, Yokota S, Yonekura K, Dehari H, Arata S, Kohama G, Fujii N. Interferon-g downregulates Hsp27 expression and suppresses the negative regulation of cell death in oral squamous cell carcinoma lines. Cell Death Differ 2003;10(3): 313-322.
47. Yokota S, Kubota H, Matsuoka Y, Naitoh N, Hirata D, Minota S, Takahashi H, Fujii N, Nagata K. Prevalence of HSP47 and autoantibodies to HSP47 in the sera of patients with mixed connective tissue disease. Biochem Biophys Res Commun 2003;303(2): 413-418.
48. Yokota S, Yokosawa N, Kubota T, Okabayashi, T Arata S, Fujii N. Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1. J Biol Chem 2003;278(43): 41654-41660.
49. Yokota S, Okabayashi T, Yokosawa N, Fujii N. Growth arrest of epithelial cells during measles virus infection is caused by upregulation of interferon regulatory factor-1. J Virol 2004;78(9): 4591-4598.
50. Kuronuma K, Sano H, Kato K, Kudo K, Hyakushima N, Yokota S, Takahashi H, Fujii N, Suzuki H, Kodama A, Abe S, Kuroki Y. Pulmonary surfactant protein A augments the phagocytosis of Streptococcus pneumoniae by alveolar macrophages through a casein kinase 2-dependent increase of cell surface localization of scavenger receptor A. J Biol Chem 2004;279(20): 21421-21430.
51. Yokota S, Yokosawa N, Okabayashi T, Suzutani T, Miura S, Jimbow K, Fujii N. Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway. J Virol 2004;78(12): 6282-6286.
52. Kudo K, Sano H, Takahashi H, Kuronuma K, Yokota S, Fujii N, Shimada K, Yano I, Kumazawa Y, Voelker DR, Abe S, Kuroki Y. Pulmonary collectins enhance phagocytosis of Mycobacterium avium through increased activity of mannose receptor. J Immunol 2004;172(12): 7592-7602.
53. Shimizu T, Yokota S, Takahashi S, Kunishima Y, Takeyama K, Masumori N, Takahashi A, Matsukawa M, Itoh N, Tsukamoto T, Fujii N. Membrane-anchored CD14 is important for the induction of interleukin-8 by lipopolysaccharide and peptidoglycan in uroepithelial cells. Clin Diagn Lab Immunol 2004;11(5): 969-976.
54. Yonekura K, Yokota S, Tanaka S, Kubota H, Fujii N, Matsumoto H, Chiba S. Prevalence of anti-heat shock protein antibodies in cerebrospinal fluids of patients with Guillain-Barre syndrome. J Neuroimmunol 2004;156(1-2): 204-209.
55. Yokota S, Sato K, Yoshida S, Hayashi T, Matsuda K, Kuwahara O, Habadera S, Kobayashi K, Ueno R, Akizawa H, Fujii N. Macrolide-resistant Streptococcus pneumoniae clinical isolates that occur in Hokkaido prefecture, Japan. J Infect Chemother 2004;10(5): 284-287.
56. Horita N, Yokota S, Fuse S, Takamuro M, Tomita H, Sato K, Fujii N, Tsutsumi H. The throat flora and its mitogenic activity in patients with Kawasaki disease. Microbiol Immunol 2004;48(11): 899-903.
57. Chiba S, Sugiyama T, Yonekura K, Tanaka S. Matsumoto H, Fujii N, Yokota S, Hirayama T. An antibody to VacA of Helicobacter pylori in the CSF of patients with Miller-Fisher syndrome. Neurology 2004;63(11): 2184-2186.
58. Kubota T, Yokosawa N, Yokota S, Fujii N, Tashiro M, Kato A. Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J Virol 2005;79(7): 4451-4459.
59. Konno M, Fujii N, Yokota S, Sato K, Takahashi M, Sato K, Mino E, Sugiyama T. Five-year follow-up study of mother-to-child transmission of Helicobacter pylori infection detected by random amplified polymorphic DNA fingerprinting method. J Clin Microbiol 2005;43(5): 2246-2250.
60. Yokota S, Yokosawa N, Okabayashi T, Suzutani T, Fujii N. Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 confers efficient viral replication. Virology 2005;338(1): 173-181.
61. Iki S, Yokota S, Okabayashi T, Yokosawa N, Nagata K, Fujii N. Serum-dependent expression of promyelocytic leukemia protein suppresses propagation of influenza virus. Virology 2005;343(1): 106-115.
62. Chiba S, Yokota S, K. Yonekura K, Tanaka S, Furuyama H, Kubota H, Fujii N, Matsumoto H. Autoantibodies against HSP70 family proteins in cerebrospinal fluid from patients with multiple sclerosis. J Neurol Sci 2006;240(1-2): 39-43.
63. Okabayashi T, Kariwa H, Yokota S, Iki S, Indoh T, Yokosawa N, Takashima I, Tsutsumi H, Fujii N. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol 2006;78(4): 417-424.
64. Yokota S, Minota S, Fujii N. Anti-HSP auto-antibodies enhance HSP-induced proinflammatory cytokine production in human monocytic cells via Toll-like receptors. Int Immunol 2006;18(4): 573-580.
65. Furuyama H, Chiba S, Okabayashi T, Yokota S, Nonaka M, Imai T, Fujii N, Matsumoto H. Single nucleotide polymorphisms and functional analysis of MxA promoter region in multiple sclerosis. J Neurol Sci 2006;249(2): 153-157.
66. Harimaya A, Yokota, S, Sato K, Koizumi J, Yamazaki N, Himi T, Fujii N. Alternations of pbp1a, pbp2b, and pbp2x in Streptococcus pneumoniae isolates from children with otolaryngological infectious disease in the Sapporo district of Japan. J Infect Chemother 2006;12(6): 366-371.
67. Harimaya A, Takada R, Himi T, Yokota S, Fujii N. Evidence of local antibody response against Alloiococcus otitidis in the middle ear cavity of children with otitis media. FEMS Immunol Med Microbiol 2007;49(1): 41-45.
68. Yokota S, Harimaya A, Sato K, Somekawa Y, Himi T, N. Fujii N. Colonization and turnover of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in otitis-prone children. Microbiol Immunol 2007;51(2): 223-230.
69. Yokota S, Fujii N. Contributions of the lipopolysaccharide outer core oligosaccharide region on the cell surface properties of Pseudomonas aeruginosa. Comp Immunol Microbiol Infect Dis 2007;30(2): 97-109.
70. Indoh H, Yokota S, Okabayashi T, Yokosawa N, Fujii N. Suppression of NF-kB and AP-1 activation in monocytic cells persistently infected with measles virus. Virology 2007;361(2): 294-303.
71. Harimaya A, Yokota S, Sato K, Yamazaki N, Himi T, Fujii N. High prevalence of erythromycin resistance and macrolide-resistance genes, mefA and ermB, in Streptococcus pneumoniae isolates from the upper respiratory tracts of children in the Sapporo district, Japan. J Infect Chemother 2007;13(4): 219-223.
72. Yokota S, Ohnishi T, Muroi M, Tanamoto K, Fujii N, Amano K. Highly-purified Helicobacter pylori LPS preparations induce weak inflammatory reactions and utilize Toll-like receptor 2 complex but not Toll-like receptor 4 complex. FEMS Immunol Med Microbiol 2007;51(1): 140-148.
73. Yokota S, Okabayashi T, Yokosawa N, Fujii N. Measles virus P protein suppresses Toll-like receptor signal through upregulation of ubiquitin-modifying enzyme A20. FASEB J 2008;22(1): 74-83.
74. Yokota S, Ohkoshi Y, Sato K, Fujii N. Emergence of fluoroquinolone-resistant Haemophilus influenzae strains among elderly patients but not among children. J Clin Microbiol 2008;46(1): 361-365.
75. Yokota S, Konno M, Mino E, Sato K, Takahashi M, Fujii N. Enhanced Fe ion-uptake activity in Helicobacter pylori strains isolated from patients with iron-deficiency anemia. Clin Infect Dis 2008;46(4): e31-e33.
76. Ohkoshi Y, Yokota S, Sato K, Hayashi T, Matsuda K, Kuwahara O, Akizawa H, Fujii N. Antibiotic susceptibility of Haemophilus influenzae strains isolated from various clinical sources in Hokkaido Prefecture, Japan. J Infect Chemother 2008;14(2): 93-98.
77. Harimaya A, Yokota S, Sato K, Himi T, Fujii N. Remarkably high prevalence of fts I gene mutations in Haemophilus influenzae isolates from upper respiratory tract infections in children of the Sapporo district, Japan. J Infect Chemother 2008;14(2): 223-227.
78. Okabayashi T, Yokota S, Ohkoshi Y, Ohuchi H, Yoshida Y, Kikuchi M, Yano K, Fujii N. Occurrence of Norovirus infections unrelated to Norovirus outbreaks in an asymptomatic food handler population. J Clin Microbiol 2008;46(6): 1985-1988.
79. Konno M, Yokota S, Suga T, Takahashi M, Sato K, Fujii N. Predominance of mother-to-child transmission of Helicobacter pylori infection detected by random amplified polymorphic DNA fingerprinting analysis in Japanese families. Pediatr Infect Dis J 2008;27(11): 999-1003.
80. Kakugawa T, Yokota S, Mukae H, Kubota H, Sakamoto N, Mizunoe S, Matsuoka Y, Kadota J, Fujii N, Nagata K, Kohno S. High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis. BMC Pulm Med 2008;8: 23.
81. Okabayashi T, Yokota S, Tsutsumi H, Fujii N. Fosfomycin suppresses chemokine induction in airway epithelial cells infected with the respiratory syncytial virus. Clin Vaccine Immunol 2009;16(6): 859-865.
82. Yokota S, Ohkoshi Y, Sato K, Fujii N. High prevalence of b-lactam-resistant type b Haemophilus influenzae isolates derived from respiratory tract specimens in Japanese patients. Int J Infect Dis 2009;13(5): 584-588.
83. Yokota S, Ohkoshi Y, Fujii N. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Diagn Microbiol Infect Dis 2009;65(1): 76-80.
84. Hashimoto K, Ishibashi K, Ishioka K, Zhao D, Sato M, Ohara S, Abe Y, Kawasaki Y, Sato Y, Yokota S, Fujii N, Peebles Jr. RS, Hosoya M, Suzutani T. RSV replication is attenuated by counteracting expression of the suppressor of cytokine signaling (SOCS) molecules. Virology 2009;391(2): 162-170.
85. Yamaguchi M, Minamide Y, Terao Y, Isoda R, Ogawa T, Yokota S, Hamada S, Kawabata S. Nrc of Streptococcus pneumoniae suppresses capsule expression and enhances anti-phagocytosis. Biochem Biophys Res Commun 2009;390(1): 155-160.
86. Yokota S, Okabayashi T, Rehli M, Fujii N, Amano K. Helicobacter pylori lipopolysaccharides upregulate Toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infect Immun 2010;78(1): 468-476.
87. Yokota S, Chiba S, Furuyama H, Fujii N. Cerebrospinal fluids containing anti-HSP70 autoantibodies from multiple sclerosis patients augment HSP70-induced proinflammatory cytokine production in monocytic cells. J Neuroimmunol 2010;218(1-2): 129-133.
88. Sawada K, Ariki S, Kojima T, Saito A, Yamazoe M, Nishitani C, Shimizu T, Tahakashi M, Mitsuzawa H, Yokota S, Sawada N, Fujii N, Takahashi H, Kuroki Y. Pulmonary collectins protect macrophages against pore-forming activity of Legionella pneumophila and suppress its intracellular growth. J Biol Chem 2010;285(11): 8434-8443.
89. Kamiya T, Okabayashi T, Yokota S, Kan Y, Ogino J, Yamashita T, Fujii N, Jimbow K. Increased caspase-2 activity is associated with induction of apoptosis in IFN-b sensitive melanoma cell lines. J Interferon Cytokine Res 2010;30(5): 349-357.
90. Uemura S, Yokota S, Mizuno H, Sakawaki E, Sawamoto K, Tanno K, Mori K, Asai Y, Fujii N. Acquisition by Pseudomonas aeruginosa isolates of a transposon encoding an extended-spectrum b-lactamase SHV-12 during the clinical course of a burn patient. Antimicrob Agents Chemother 2010;54(9): 3956-3959.
91. Yokota S, Okabayashi T, Yoto Y, Hori T, Tsutsumi H, Fujii N. Fosfomycin suppresses RS-virus-induced Streptococcus pneumoniae and Haemophilus influenzae adhesion to respiratory epithelial cells via the platelet-activating factor receptor. FEMS Microbiol Lett 2010;310(1): 84-90.
92. Yokota S, Okabayashi T, Fujii N. Measles virus C protein suppresses gamma-activated factor formation and virus-induced cell growth arrest. Virology 2011;414(1): 74-82.
93. Sato T, Yokota S, Uchida I, Okubo T, Ishihara K, Fujii N, Tamura Y. A fluoroquinolone-resistant Escherichia coli clinical isolate without quinolone resistance-determining region mutations found in Japan. Antimicrob Agents Chemother 2011;55(8): 3964-3965.
94. Okabayashi T, Kojima T, Masaki T, Yokota S, Imaizumi T, Tsutsumi H, Himi T, Fujii N, Sawada N. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 2011;160(1-2): 360-366.
95. Yokota S, Sato T, Okubo T, Ohkoshi Y, Okabayashi T, Kuwahara O, Tamura Y, Fujii N. Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15 nonproducing) strains isolated in Japan. Chemotherapy 2012;58(1): 52-59.
96. Yokota S, Okabayashi T, Hirakawa S, Tsutsumi H, Himi T, Fujii N. Clarithromycin suppresses human respiratory syncytial virus infection-induced Streptococcus pneumoniae adhesion and cytokine production in a pulmonary epithelial cell line. Mediators Inflamm 2012;2012: 528568.
97. Yokota S, Amano K, Nishitani C, Ariki S, Kuroki Y, Fujii N. Implication of antigenic conversion of Helicobacter pylori lipopolysaccharides that involve interaction with surfactant protein D. Infect Immun 2012;80(8): 2956-2962.
98. Amano K, Yokota S, Monteiro MA. Comparison of the serological reactivity of lipopolysaccharides from Japanese and Western strains of Helicobacter pylori to sera from H. pylori-positive humans. ISRN Microbiol 2012;2012: 162816.
99. Kan Y, Okabayashi T, Yokota S, Yamamoto S, Fujii N, Yamashita T. Imiquimod suppresses propagation of herpes simplex virus type 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol 2012;86(19): 10338-10346.
100. Yokota S, Toita N, Yamamoto S, Fujii N, Konno M. Positive relationship between a polymorphism in Helicobacter pylori neutrophil-activating protein A gene and iron-deficiency anemia. Helicobacter 2013;18(2): 112-116.
101. Sato T, Yokota S, Okubo T, Ishihara K, UenoH, Muramatsu Y, Fujii N, Tamura Y. Contribution of the AcrAB-TolC efflux pump to high-level fluoroquinolone resistance in Escherichia coli isolated from dogs and humans. J Vet Med Sci 2013;75(4): 407-414.
102. Shiraishi T, Yokota S, Morita N, Fukiya S, Tomita S, Tanaka N, Okada S, Yokota A. Characterization of a Lactobacillus gasseri JCM1131T lipoteichoic acid with a novel glycolipid anchor structure. Appl Environ Microbiol 2013;79(10): 3315-3318.
103. Sato T, Yokota S, Uchida I, Okubo T, Usui M, Kusumoto M, Akiba M, Fujii N, Tamura Y. Fluoroquinolone resistance mechanisms in an Escherichia coli isolate, HUE1, without quinolone resistance-determining region mutations. Front Microbiol 2013;4: 125.
104. Kakugawa T, Yokota S, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, Sakamoto N, Kubota H, Mine M, Matsuoka Y, Mukae H, Nagata K, Kohno S. 2013. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones 2013;18(5): 581-590.
105. Obata K, Kojima T, Masaki T, Okabayashi T, Yokota S, Hirakawa S, Nomura K, Takasawa A, Murata M, Tanaka S, Fuchimoto J, Fujii N, Tsutsumi H, Himi T, Sawada N. Curcumin prevents replication of respiratory syncytial virus and the epithelial response to it in human nasal epithelial cells. PLOS ONE 2013;8(9): e70225.
106. Hirakawa S, Kojima N, Obata K, Okabayashi T, Yokota S, Nomura K, Obonai T, Fuchimoto J, Himi T, Tsutsumi H, Sawada N. Marked induction of matrix metalloproteinase-10 by respiratory syncytial virus infection in human nasal epithelial cells. J Med Virol 2013;85(12): 2141-2150.
107. Toita N, Yokota S, Fujii N, Konno M. Clonality analysis of Helicobacter pylori in patients isolated from several biopsy specimens and gastric juice in a Japanese urban population by random amplified polymorphic DNA fingerprinting. Gastroenterol Res Pract 2013;2013: 721306.
108. Kakugawa T, Yokota S, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, Sakamoto N, Kubota H, Mine M, Matsuoka Y, Mukae H, Nagata K, Kohno, S. Serum heat shock protein 47 levels in patients with drug-induced lung disease. Respir Res 2013;14: 133.
109. Fuchimoto J, Kojima T, Okabayashi T, Masaki T, Ogasawara N, Obata K, Nomura K, Hirakawa S, Kobayashi N, Shigyo T, Yokota S, Fujii N, Tsutsumi H, Himi T, Sawada N. 2013. Humulone suppresses replication of respiratory syncytial virus and release of IL-8 and RANTES in normal human nasal epithelial cells. Med Mol Morphol 2013;46(4): 203-209.
110. Tsukamoto N, Ohkoshi Y, Okubo T, Sato T, Kuwahara O, Fujii N, Tamura Y, Yokota S. High prevalence of cross-resistance to aminoglycosides in fluoroquinolone-resistant Escherichia coli clinical isolates. Chemotherapy 2013;59(5): 379-384.
111. Sato T, Yokota S, Okubo T, Fujii N, Tamura Y. Phylogenetic association of fluoroquinolone and cephalosporin resistance of D-O1-ST648 Escherichia coli carrying the blaCMY-2 from faecal samples of dogs in Japan. J Med Microbiol 2014;63(2): 263-270.
112. Kakugawa T, Yokota S, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, Sakamoto N, Kubota H, Mine M, Matsuoka Y, Mukae H, Nagata K, Kohno, S. Serum heat shock protein 47 levels are elevated in acute interstitial pneumonia. BMC Pulm Med 2014;14: 48.
113. Yamamoto S. Subedi GP, Hanashima S, Satoh T, Otaka M, Wakui H, Sawada K, Yokota S, Yamaguchi Y, Kubota H, Itoh H. ATPase activity and ATP-dependent conformational change in the co-chaperone HSP70/HSP90-organizing protein (HOP). J Biol Chem 2014;289(14): 9880-9886.
114. Okubo T, Sato T, Yokota S, Usui M, Tamura Y. Comparison of broad-spectrum cephalosporin-resistant Escherichia coli isolated from dogs and humans in Hokkaido, Japan. J Infect Chemother 2014;20(4): 243-249.
115. Sato T, Okubo T, Usui M, Yokota S, Tamura Y. Association of veterinary third-generation cephalosporin use with the risk of emergence of extended-spectrum-cephalosporin resistance in Escherichia coli from dairy cattle in Japan. PLOS ONE 2014;9(4): e96101.
116. Sato T, Yokota S, Ichihashi R, Miyauchi T, Okubo T, Ishihara K, Fujii N, Tamura Y. Isolation of Escherichia coli strains with AcrAB-TolC efflux pump-associated intermediate interpretation or Ａresistance to fluoroquinolone, chloramphenicol, and aminopenicillin from dogs admitted to a university veterinary hospital. J Vet Med Sci 2014;76(7): 937-945.
117. Yamamoto S, Wakui H, Kubota H, Komatsuda A, Itoh H, Yokota S. Aminoglycosides suppress the protein folding activity of the molecular chaperone HSC70: implication of a structure-activity relationship. Chemotherapy 2014;60(1): 37-46.
118. Yokota S, Konno M, Fujiwara S, Toita N, Takahashi M, Yamamoto S, Ogasawara N, Shiraishi T. Intrafamilial, preferentially mother-to-child and intraspousal, Helicobacter pylori infection in Japan determined by mutilocus sequence typing and random amplified polymorphic DNA fingerprinting. Helicobacter 2015;20(5): 334-342.
119. Grave E, Yokota S, Yamamoto S, Tamura A, Ohtaki-Mizoguchi T, Yokota K, Oguma K, Fujiwara K, Ogawa N, Okamoto T, Otaka M, Itoh H. Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology. Sci Rep 2015;5: 13738.
120. Jinushi M, Yamamoto S, Ogasawara N, Nagano H, Hashimoto S, Tsutsumi H, Himi T, Yokota S. Measles virus genotype D wild strains suppress interferon-stimulated gene expression more potently than laboratory strains in SiHa cells. Viral Immunol 2016;29(5): 296-306.
121. Yamamoto K, Yamamoto S, Ogasawara N, Takano K, Shiraishi T, Sato T, Miyata R, Kakui T, Kamekura R, Kojima T, Tsutsumi H, Himi T, Yokota S. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial response by modulating activation of interferon regulatory factor-3. Pharmacol Res 2016;111: 804-814.
122. Hashimoto S, Yamamoto S, Ogasawara N, Sato T, Yamamoto K, Katoh H, Kubota T, Shiraishi T, Kojima T, Himi T, Tsutsumi H, Yokota S. Mumps virus induces protein-kinase-R-dependent stress granules, partly suppressing type III interferon production. PLOS ONE 2016;11(8): e0161793.
123. Sato T, Fukuda A, Suzuki Y, Shiraishi T, Honda H, Yamamoto S, Ogasawara N, Shinagawa M, Takahashi S, Usui M, Tamura Y, Yokota S. Pathogenic lineage of mcr-negative colistin-resistant Escherichia coli, Japan, 2008-2015. Emerg Infect Dis 2016;22(12):2223-2225.
124. Uemura S, Yokota S, Shiraishi T, Kitagawa M, Hirayama S, Kyan R, Mizuno H, Sawamoto K, Inoue H, Miyamoto A, Narimatsu E. Adaptive cross-resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa induced by topical dosage of neomycin. Chemotherapy 2017;62(2): 121-127.
125. Sato, T, Suzuki Y, Shiraishi T, Honda H, Shinagawa M, Yamamoto S, Ogasawara N, Takahashi H, Takahashi S, Tamura Y, Yokota, S. Tigecycline nonsusceptibility occurs exclusively in fluoroquinolone-resistant Escherichia coli clinical isolates, including the major multidrug-resistant lineages O25b:H4-ST131-H30R and O1-ST648. Antimicrob Agents Chemother 2017;61(2): e01654-16.
126. Yamamoto S, Ogasawara N, Yamamoto K, Uemura C, Takaya Y, Shiraishi T, Sato T, Hashimoto S, Tsutsumi H, Takano K, Himi T, Yokota S. Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-κB-mediated cytokine production. Biochem Biophys Res Commun 2017;483(3): 911-916.
127. Yamamoto S, Okamoto T, Ogasawara N, Hashimoto S, Shiraishi T, Sato T, Yamamoto K, Tsutsumi H, Takano K, Himi T, Itoh H, Yokota S. NIP-SNAP-1 and -2 mitochondrial proteins are maintained by heat shock protein 60. Biochem Biophys Res Commun 2017;483(3): 917-922.
128. Ohkoshi Y, Sato T, Suzuki Y, Yamamoto S, Shiraishi T, Ogasawara N, Yokota S. Mechanism of reduced susceptibility to fosfomycin in Escherichia coli clinical isolates. BioMed Res Int 2017; 2017: 5470241.
129. Sato Y, Koshizuka T, Ishibashi K, Hashimoto K, Ishioka K, Ikuta K, Yokota S, Fujii N, Suzutani T. Involvement of herpes simplex virus type 1 UL13 protein kinase in induction of SOCS genes, the negative regulators of cytokine signaling. Microbiol Immunol 2017;61(5): 159-167.
130. Sato T, Higuchi H, Yokota S, Tamura Y. Mycoplasma bovis isolates from dairy calves in Japan have less susceptibility than a reference strain to all approved macrolides associate with a point mutation (G748A) combined with multiple species-specific nucleotide alterations in 23S rRNA. Microbiol Immunol 2017;61(6): 215-224.
131. Kitagawa M, Shiraishi T, Yamamoto S, Kutomi R, Ohkoshi Y, Sato T, Wakui H, Itoh H, Miyamoto A, Yokota S. Novel antimicrobial activities of a peptide derived from a Japanese soybean fermented food, Natto, against Streptococcus pneumoniae and Bacillus subtilis group strains. AMB Express 2017;7: 127.
132. Kaneko Y, Kohno T, Kakui T, Takano K, Ogasawara N, Miyata R, Kikuchi S, Konno T, Ohkuni T, Yajima R, Kakiuchi A, Yokota S, Himi T, Kojima T. The role of transcriptional factor p63 in regulation of epithelial barrier and ciliogenesis of human nasal epithelial cells. Sci Rep 2017;7(1): 10935.
133. Sato T, Ohkoshi Y, Wada T, Fukushima Y, Murabayashi H, Takakuwa Y, Nishiyama K, Shiraishi T, Nakajima C, Suzuki Y, Yokota S. Complete genome sequence of multidrug-resistant Streptococcus pneumoniae serotype 19F isolated from an invasive infection in Sapporo, Japan. Genome Announc 2017;44(5): e01239-17.
134. Sato T, Harada K, Usui M, Tsuyuki Y, Shiraishi T, Tamura Y, Yokota S. Tigecycline susceptibility of Klebsiella pneumoniae complex and Escherichia coli isolates from companion animals: the prevalence of tigecycline-nonsusceptible K. pneumoniae complex, including internationally expanding human pathogenic lineages. Microb Drug Resist 2018, in press.
135. Fukuda A, Sato T, Shinagawa M, Takahashi S, Asai T, Yokota S, Usui M, Tamura Y. High prevalence of mcr-1, mcr-3, and mcr-5 in Escherichia coli derived from diseased pigs in Japan. Int J Antimicrob Agents 2018;51(1):163-164.
136. Yamamoto K, Ogasawara N, Yamamoto S, Takano K, Shiraishi T, Sato T, Tsutsumi H, Himi T, Yokota S. Evaluation of consistency in quantification of gene copy number by real-time reverse transcription quantitative polymerase chain reaction and virus titer by plaque-forming assay for human respiratory syncytial virus. Microbiol Immunol 2018;62(2):90-98.
137. Shiraishi T, Yokota S. Sato Y, Ito T, Fukiya S, Yamamoto S, Sato T, Yokota A. Lipoteichoic acids are embedded in cell walls during logarithmic phase, but exposed on membrane vesicles in Lactobacillus gasseri JCM 1131T. Benef Microbes 2018;9(4):653-662.
138. Ohkoshi Y, Sato T, Wada T, Fukushima Y, Murabayashi H, Takakuwa Y, Nishiyama K, Honda H, Shiraishi T, Kuronuma K, Takahashi H, Nakajima C, Suzuki Y, Yokota S. Whole genome analysis of a multidrug-resistant Streptococcus pneumoniae isolate from a patient with invasive pneumococcal infection developing disseminated intravascular coagulation. J Infect Chemother 2018;24(8):674-681.
139. Yokota S, Hakamada H, Yamamoto S, Sato T, Shiraishi T, Shinagawa M, Takahashi S. Release of large amounts of lipopolysaccharides from Pseudomonas aeruginosa cells reduces their susceptibility to colistin. Int J Antimicrob Agents 2018;51(6):888-896.
140. Sato T, Fukuda A, Usui M, Shinagawa M, Shiraishi T, Tamura Y, Takahashi S, Yokota S. Isolation of a mcr-1-harbouring Escherichia coli isolate from a human clinical setting in Sapporo, Japan. J Glob Antimicrob Resist 2018;13:20-21.
141. Sato T, Shiraishi T, Hiyama Y, Honda H, Shinagawa M, Usui M, Kuronuma K, Masumori N, Takahashi S, Tamura Y, Yokota S. Contribution of novel amino acid alterations in PmrA or PmrB to colistin resistance in mcr-negative Escherichia coli clinical isolates, including major multidrug-resistant lineages O25b:H4-ST131-H30Rx and non-x. Antimicrob Agents Chemother 2018;62(9):e00864-18.
142. Kuromuma K, Honda H, Mikami T, Saito A, Ikeda K, Otsuka M, Chiba H, Yamada G, Sato T, Yokota S, Takahashi H. Response to pneumococcal vaccine in interstitial lung disease patients: Influence of systemic immunosuppressive treatment. Vaccine 2018;36(33):4968-4972.
143. Honda H, Sato T, Shinagawa M, Fukushima Y, Nakajima C, Suzuki Y, Shiraishi T, Kuronuma K, Takahashi S, Takahashi H, Yokota S. Multiclonal expansion and high prevalence of β-lactamase-negative Haemophilus influenzae with high-level ampicillin resistance in Japan and susceptibility to quinolones. Antimicrob Agents Chemother 2018;62(9):e00851-18.
144. Kaga H, Komatsuda A, Yamamoto S, Kikuchi T, Kamata M, Sato A, Odaka M, Yokota S, Takahashi N, Wakui H. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA. Clin Exp Nephrol 2019; 23(4): 465-473.
145. Hiyama Y, Takahashi S, Sato T, Shinagawa M, Fukushima Y, Nakajima C, Suzuki Y, Masumori N, Yokota S. Evaluation of susceptibilities to carbapenems and faropenem against cephalosporin-resistant Neisseria gonorrhoeae clinical isolates with penA mosaic alleles. Microb Drug Resist 2019; 25(3): 427-433.
146. Shiraishi T, Yamamoto S, Yokota S. Structural analysis of the lipoteichoic acid anchor glycolipid: Comparison of methods for degradation of the glycerophosphate backbone polymer. J Microbiol Methods 2019; 166: 105726.
147. Saeki M, Sato T, Furuya D, Yakuwa Y, Sato Y, Kobayashi R, Ono M, Nirasawa S, Tanaka M, Nakafuri H, Nakae M, Shinagawa M, Asanuma K, Yanagihara N, Yokota S, Takahashi S. Clonality investigation of clinical Escherichia coli isolates by polymerase chain reaction-based open-reading frame typing method. J Infect Chemother 2020; 26: 38-42.
148. Honda H, Sato T, Shinagawa M, Fukushima Y, Nakajima C, Suzuki Y, Kuronuma K, Takahashi S, Takahashi H, Yokota S. In vitro derivation of fluoroquinolone-resistant mutants from multiple lineages of Haemophilus influenzae and identification of mutations associated with fluoroquinolone resistance. Antimicrob Agents Chemother 2020; 64(2): e01500-19.
149. Yamamoto K, Sato T, Hikiji Y, Katsuyama A, Matsumaru T, Yakushiji F, Yokota S, Ichikawa S. Synthesis and biological evaluation of a MraY selective analogue of tunicamycins. Nucleosides Nucleotides Nucleic Acids 2020; 39(1-3):349-364.
150. Suzuki Y, Sato T, Fukushima Y, Nakajima C, Suzuki Y, Takahashi S, Yokota S. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 2020; 55(4):105919.
151. Ohkoshi Y, Sato T, Murabayashi H, Sakai K, Takakuwa Y, Fukushima Y, Nakajima C, Suzuki Y, Yokota S. Campylobacter upsaliensis isolated from a giant hepatic cyst. J Infect Chemother 2020; 26(7):752-755.
152. Sato T, Wada T, Shinagawa M, Fukushima Y, Nakajima C, Suzuki Y, Takahashi S, Yokota S. Emergence of vancomycin- and teicoplanin-resistant Enterococcus faecium via vanD5-harbouring large genomic island. J Antimicrob Chemother 2020; 75(9):2411-2415.
153. Terasawa Y, Sataka C, Nakajima C, Sato T, Yamamoto K, Fukushima Y, Suzuki Y, Katsuyama A, Matsumaru T, Yakushiji F, Yokota S, Ichikawa S. Elucidating structural requirement of uridylpeptide antibiotics for antibacterial activity. J Med Chem 2020; 63(17):9803-9827.
154. Hiyama Y, Sato T, Takahashi S, Yamamoto S, Fukushima Y, Nakajima C, Suzuki Y, Yokota S, Masumori N. Sitafloxacin has a potent activity for eradication of extended spectrum β-lactamase-producing fluoroquinolone-resistant Escherichia coli forming intracellular bacterial communities in uroepithelial cells. J Infect Chemother 2020; 26(12):1272-1277.
155. Munby M, Fujiki J, Aoki K, Kawaguchi C, Nakamura K, Nakamura T, Sasaki M, Sato T, Usui M, Sawa H, Yokota S, Tamura Y, Iwano H. Whole-genome sequence of fluoroquinolone-resistant Escherichia coli HUE1, isolated in Hokkaido, Japan. Microbiol Resour Announc 2020; 9(46): e01135-20.
156. Sato T, Wada T, Nishijima S, Fukushima Y, Nakajima C, Suzuki Y, Takahashi S, Yokota S. Emergence of the novel aminoglycoside acetyltransferase variant aac(6')-Ib-D179Y and an acquisition of colistin heteroresistance in carbapenem-resistant Klebsiella pneumoniae due to a disrupting mutation in the DNA repair enzyme MutS. mBio 2020; 11(6): e01954-20.
157. Iyama S, Tatsumi H, Shiraishi T, Yoshida M, Tatekoshi A, Endo A, Ishige T, Shiwa Y, Ibata S, Goto A, Nagashima K, Horiguchi H, Fujita C, Ikeda H, Takada K, Nobuoka T, Kamihara Y, Kikuchi S, Sato T, Ohnishi H, Yokota S, Kobune M. Posible clinical outcomes using early enteral nutrition in individuals with allogeneic hematopoietic stem cell transplantation: a single-center retrospective study. Nutrition 2021; 83: 111093.
158. Sato T, Usui M, Harada K, Fukushima Y, Nakajima C, Suzuki Y, Yokota S. Complete genome sequence of an mcr-9-possessing Enterobacter asburiae strain isolated from a cat in Japan. Microbiol Resour Announc 2021; 10(26): e00281-21.
159. Sato T, Usui M, Harada K, Fukushima Y, Nakajima C, Suzuki Y, Yokota S. Complete genome sequence of an mcr-10-possessing Enterobacater roggenkampii strain isolated from a dog in Japan. Microbiol Resour Announc 2021; 10(30): e00426-21.
160. Shiraishi T, Maeno S, Kishi S, Fujii T, Tanno H, Hirano K, Tochio T, Tanizawa Y, Arita M, Yokota S, Endo A. Oligosaccharide metabolism and lipoteichoic acid production in Lactobacillus gasseri and Lactobacillus paragasseri. Microorganisms 2021; 9(8): 1590.
161. Katsuki R, Shiraishi T, Sakata S, Hirota T, Nakamura Y, Yokota S. Inhibitory effect of the glycerophosphate moiety of lipoteichoic acid from lactic acid bacteria on dexamethasone-induced atrogin-1 expression in C2C12 myotubes. J Nutr Sci Vitaminol 2021; 67(5): 351-357.
162. Mariya T, Sato T, Fujibe Y, Ishido M, Shimada H, Kubo T, Nagai Y, Arai W, Tanaka SE, Ashikawa K, Sakuraba Y, Ishioka S, Yokota S, Saito T. Next-generation sequencing of 16S rRNA for identification of invasive bacterial pathogens in formalin-fixed paraffin-embedded placental specimen: a case report of perinatal fulminant Streptococcus pyogenes infection. Mol Morphol Med 2021; 54(4): 374-379.
163. Fukushima Y, Sato T, Tsukamoto N, Nakajima C, Suzuki Y, Takahashi S, Yokota S. Clonal/subclonal changes and accumulation of CTX-M-type β-lactamase genes in fluoroquinolone-resistant Escherichia coli ST131 and ST1193 strains isolated during the past 12 years, in Japan. J Glob Antimicrob Resist 2021; 27: 150-155.
164. Sato T, Yokota S, Tachibana T, Tamai S, Maetani S, Tamura Y, Horiuchi M. Isolation of human lineage, fluoroquinolone-resistant Escherichia coli isolates from companion animals in Japan, 2020. Antibiotics 2021; 10; 1463.
165. Hiyama Y, Sato T, Takahashi S, Yamamoto S, Ogasawara N, Masumori N, Yokota S. Reduction of susceptibility to azoles and 5-fluorocytosine and growth acceleration in Candida albicans in glucosuria. Diagn Microbiol Infect Dis 2022; 102(1); 115556.
166. Okamoto K, Ishikawa A, Okawa R, Yamamoto K, Sato T, Yokota S, Chiba K, Ichikawa S. Design, synthesis and biological evaluation of simplified analogues of MraY inhibitory natural product with rigid scaffold. Bioorg Med Chem 2022; 55; 116556
167. Yamamoto K, Fujiya Y, Kuronuma K, Ogasawara N, Ohkuni T, Yokota S, Takahashi S, Takano K. Self-reported smell and taste disorders in patients with COVID-19: A Japanese single-center study. In Vivo 2022; 36(2); 918-924.
168. Takashina K, Katsuyama A, Kaguchi R, Yamamoto K, Sato T, Takahashi S, Horiuchi M, Yokota S, Ichikawa S. Solid-phase total synthesis of plusbacin A3. Org Lett 2022; 24(11); 2253-2257.
169. Matsuzaki C, Shiraishi T, Chiou T-Y, Nakashima Y, Higashiyama Y, Yokota S, Yamamoto K, Takahashi T. Role of lipoteichoic acid from the genus Apilactobacillus in inducing a strong IgA response. Appl Environ Microbiol 2022; 88(8): e0019022.
170. Takumi-Tanimukai Y, Yamamoto S, Ogasawara N, Nakabayashi S, Mizuta K, Yamamoto K, Miyata R, Kakuki T, Jitsukawa S, Sato T, Tsutsumi H, Kojima T, Takano K, Yokota S. A hydroxypropyl methylcellulose plaque assay for human respiratory syncytial virus. J Virol Methods 2022; 304: 114528.
171. Yokota K, Osaki T, Hayashi S, Yokota S, Takeuchi H, Rimbara E, Ojima H, Sato T, Yonezawa H, Shibayama K, Tokunaga K, Kamiya S, Murakami K, Kato M, Sugiyama T. Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing. Helicobacter 2022; 27(3): e12874.
172. Kurumi H, Takata T, Kanda T, Sugihara T, Kakugawa T, Yokota S, Morisaki T, Akahi T, Isomoto H. Investigating the role of heat shock protein 47 in fibrosis in Crohn’s disease. Sci Rep 2022; 12(1): 10966.
173. Sato T, Harada K, Usui M, Yokota S, Horiuchi M. Colistin susceptibility in companion animal-derived Escherichia coli, Klebsiella spp., and Enterobacter spp. in Japan: Frequent isolation of colistin-resistant Enterobacter cloacae complex. Front Cell Infect Microbiol 2022; 12: 946841.
174. Kojima N, Kojima S, Hosokawa S, Oda Y, Zenke D, Toura Y, Onohara E, Yokota S, Nagaoka M, Kuroda Y. Wall teichoic acid-dependent phagocytosis of intact cell walls of Lactiplantibacillus plantarum elicits IL-12 secretion from macrophages. Front Microbiol 2022; 13: 986396.
175. Nakaya T, Yabe M, Mashalidis EH, Sato T, Yamamoto K, Hikiji Y, Katsuyama A, Shinohara M, Minato Y, Takahashi S, Horiuchi M, Yokota S, Lee S-Y, Ichikawa S. Synthesis of macrocyclic nucleoside antibacterials and their interactions with MraY. Nat Commun 2022; 13(1): 7575.
176. Kaguchi R, Katsuyama A, Sato T, Takahashi S, Horiuchi M, Yokota S, Ichikawa S. Discovery of biologically-optimized polymyxin derivatives facilitated by peptide scanning and in situ screening chemistry. J Am Chem Soc 2023; 145(6): 3665-3681.
177. Yamamoto S, Sudo-Yokoyama Y, Ogasawara N, Yokota S. Rapid, simple, and cost-effective plaque assay for murine norovirus using microcrystalline cellulose. J Virol Methods 2023; 316: 114715.
178. Fukuzawa S, Sato T, Aoki K, Yamamoto S. Ogasawara N, Nakajima C, Suzuki Y, Horiuchi M, Takahashi S, Yokota S. High prevalence of colistin heteroresistance in specific species and lineages of Enterobacter cloacae complex derived from human clinical specimens. Ann Clin Microbiol Antimicrob 2023; 22: 60.
179. Yokota S, Tsukamoto N, Sato T, Ohkoshi Y, Yamamoto S, Ogasawara N. Serotype replacement and an increase in non-encapsulated isolates among community-acquired infections of Streptococcus pneumoniae during post-vaccine era in Japan. IJID Reg 2023; 8: 105-110.
180. Konno A, Okubo T, Enoeda Y, Uno T, Sato T, Yokota S, Yano R, Yamaguchi H. Human pathogenic bacteria on high-touch dry surfaces can be controlled by warming to human-skin temperature under moderate humidity. PLoS ONE 2023; 18(9): e0291765.
181. Nagano Y, Kuronuma K, Kitamura Y, Nagano K, Yabe H, Kudo S, Sato T, Nirasawa S, Nakae M, Horiuchi M, Yokota S, Fujiya Y, Saito A, Takahashi S, Chiba H. Pseudo-outbreak of Mycobacterium lentiflavum at a general hospital in Japan. Infect Control Hosp Epidemiol 2023, 44(11): 1809-1815.
182. Yamamoto S, Ogasawara N, Mitsuhashi Y, Takano K, Yokota S. The clarithromycin-binding proteins NIPSNAP1 and 2 regulate cytokine production through mitochondrial quality control. Sci Rep 2024; 14: 2354.
183. Nakamura M, Okayama M, Hagiwara S, Nawa T, Yokota S. Effects of metal corrosion in the pump of a dialysis machine on the sterility of the terminal dialysate by spike-and-recovery testing with bacteria. Ren Replace Ther 2024; 10: 6.
184. Hiyama Y, Yamamoto S, Sato T, Ogasawara N, Masumori N, Takahashi S, Yokota S. Affinity of β-lactam antibiotics for Neisseria gonorrhoeae penicillin-binding protein 2 having wild, cefxime-reduced-susceptible, and cepharosporin (ceftriaxone)-resistant penA alleles. Microb Drug Resist 2024; 30(3): 141-146.
185. Sato T, Uemura K, Yasuda M, Maeda A, Minamoto T, Harada K, Sugiyama M, Ikushima S, Yokota S, Horiuchi M, Takahashi S, Asai T. Traces of pandemic fluoroquinolone-resistant Escherichia coli clone ST131 transmitted from human society to aquatic environments and wildlife in Japan. One Health 2024; 18: 100715
(邦文）
1. 横田伸一，佐藤清，吉田繁，藤井暢弘．フルオロキノロン耐性 Streptococcus pneumoniae の検出状況と分子疫学的検討．感染症学雑誌 2004; 78(5): 428-434.
2. 横田伸一，岡林環樹，要藤裕孝，堤裕幸，藤井暢弘．RSウイルス感染による肺炎球菌の細胞接着増強に対するホスホマイシンの抑制効果．Bacterial Adhesion and Biofilm 2009;23:57-63.
3. 花木秀明，横田伸一，村谷哲郎：座談会．キノロン系抗菌薬の正しい使い方を考える～基礎の立場から～．新薬と臨床 2009;58:989-1000．
4. 今野武津子，横田伸一，藤井暢弘．Helicobacter pylori の主要な感染経路は母子感染である―random amplified polymorphic DNA fingerprinting法による検討―．日本ヘリコバクター学会誌 2010; 11(2): 59-65．
5. 横田伸一，大越康雄，藤井暢弘．フルオロキノロン耐性肺炎球菌，インフルエンザ菌に対する各種キノロン系抗菌薬の活性比較．日本臨床微生物学雑誌 2011;21(1): 17-24.
6. 山本圭佑，小笠原徳子，山本聡，堤裕幸，氷見徹夫，横田伸一．クラリスロマイシンは気道上皮細胞でRSウイルスによって誘導されるインターフェロンの産生をIRF-3を介して調整する．Jpn J Antibiot 2017;70(suppl. A):19-24.
7. 横田伸一，山本聡，小笠原徳子，植村知加，高谷芳明，伊藤英晃，山本圭佑，白石宗，佐藤豊孝，氷見徹夫．クラリスロマイシンの炎症反応修飾作用の分子機構の解明―気道上皮細胞のクラリスロマイシン結合タンパク質の同定と機能解明―．Jpn J Antibiot 2017;70(suppl. A):60-64.
8. 戸板成昭，藤原伸一，高橋美智子，今野武津子，横田伸一．家族内発症のCrohn病３家系７症例における臨床的特徴の比較検討ならびに疾患関連遺伝子（TNFSF15）の解析．臨牀小児医学 2017;65(1-6): 11-14.
9. 横田伸一．感染症に対峙する社会のありかた－新型コロナウイルス感染症から考える－．北海道生命倫理研究 2022;10: 1-12.
10. 山本圭佑，藤谷好弘，山直也，黒沼幸治，小笠原徳子，横田伸一，高橋聡，高野賢一．COVID-19 における嗅裂閉鎖所見と嗅覚障害の検討．日本耳鼻咽喉科免疫アレルギー感染症学会会誌 2022; 2(2): 49-54.
総説
1. Yokota S, Fujii N: Immunomodulatory activities of extracellular heat shock proteins and their autoantibodies. Microbiol Immunol 2010;54(5): 299-307.
2. Yokota S, Okabayashi T, Fujii N: The battle between virus and host: modulation of Toll-like receptor signaling pathways by virus infection. Mediators Inflamm 2010;2010: 184328.
3. Shiraishi T, Yokota S, Fukiya T, Yokota A. Structural diversity and biological significance of lipoteichoic acid in Gram-positive bacteria: Focusing on beneficial probiotic lactic acid bacteria. Biosci Microbiota Food Health 2016;35(4): 147-161.
（邦文）
1. 横田伸一：緑膿菌表層内毒素リポ多糖の構造と機能．日本臨床 1991; 49(10):2233-2238.
2. 天野憲一，横田伸一：Helicobacter pyloriリポ多糖の構造と血清学的特異性．日本細菌学雑誌 2001; 56(2):421-433．
3. 横田伸一，横沢紀子，岡林環樹，藤井暢弘：ウイルスによるJAK/STAT情報伝達系抑制の多様性．蛋白質核酸酵素 2004; 49: 517-525.
4. 藤井暢弘，横田伸一，横沢紀子，岡林環樹：ウイルスによるインターフェロン情報伝達系抑制の分子機構．ウイルス 2004; 54:160-178．
5. 藤井暢弘，横田伸一：感染症－今、何が問題となっているのか？ 4. 腸管出血性大腸菌O157感染症．北海道医報 2005; 1041:36-43．
6. 横田伸一，横沢紀子，岡林環樹，藤井暢弘：ウイルスの宿主自然免疫系からの回避戦略．札幌医科大学雑誌 2005; 74:17-22.
7. 藤井暢弘，横田伸一，横沢紀子，岡林環樹：HSV-1によるインターフェロンシステム抑制の分子機構. 日本臨床 2006; 64 (suppl. 3):171-177．
8. 藤井暢弘，横田伸一，横沢紀子，岡林環樹．ウイルス感染によるTLR情報伝達系抑制の分子機構．自然免疫抑制の全貌解明にむけて．蛋白質核酸酵素 2008; 53;710-719．
9. 藤井暢弘，横田伸一，横沢紀子，岡林環樹：ウイルス感染と自然免疫．臨床検査 2009; 53(1):17-27．
10. 横田伸一，藤井暢弘，天野憲一：Helicobacter pyloriリポ多糖の構造および生物活性の特異性に関する研究－発癌に関わる病原因子としての役割－（Award Report 第6回小林六造記念ヘリコバクター賞）．日本ヘリコバクター学会誌 2010; 11(2):53-58．
11. 堤裕幸，平川賢史，正木智之，氷見徹夫，岡林環樹，横田伸一，藤井暢弘，小島隆，澤田典均：RSウイルス感染症と喘鳴・喘息．小児耳鼻咽喉科 2010; 31:248-252．
12. 横田伸一，上村修二，藤井暢弘，浅井康文：多剤耐性緑膿菌（MDRP）の耐性機構．ICUとCCU 2010; 34(11):973-979．
13. 横田伸一，今野武津子，藤井暢弘：Helicobacter pyloriと鉄欠乏性貧血．臨床と微生物 2011; 38(1):21-25．
14. 今野武津子，戸板成昭，横田伸一．H. pylori感染症関連疾患と除菌治療の意義－鉄欠乏貧血．日本臨床 2013; 71(8):1462-1466．
15. 氷見徹夫，高野賢一，大國毅，小笠原徳子，正木智之，小幡和史，堤裕幸，小島隆，澤田典均，横田伸一．ウイルス性上気道感染での免疫応答と鼻粘膜上皮の役割．耳鼻咽喉科展望 2013; 56:162-177.
16. 氷見徹夫，高野賢一，山下恵司，小笠原徳子，正木智之，小幡和史，堤裕幸，小島隆，一宮慎吾，澤田典均，横田伸一．扁桃・アデノイドはなぜあるのか？鼻はなにをしているのか？―小児の粘膜免疫・粘膜防御最前線―．小児耳鼻咽喉科 2013; 34:239-244.
17. 氷見徹夫，高野賢一，大國毅，小笠原徳子，正木智之，小幡和史，堤裕幸，小島隆，澤田典均，横田伸一．ウイルス性炎症における上気道粘膜の役割―鼻粘膜上皮機能解析から炎症制御戦略を探る―．日本耳鼻咽喉科感染症・エアロゾル学会会誌 2014 ;2:1-5.
18. 今野武津子，横田伸一，高橋美智子，藤原伸一，大崎敬子，神谷茂．日本人小児の最近のピロリ菌感染率と感染経路について．日本ヘリコバクター学会誌 2014; 15(2): 68-74.
19. 小笠原徳子，横田伸一，氷見徹夫．ウイルス性呼吸器感染症―RSウイルス・ライノウイルス．感染と抗菌薬 2014; 17(1):68-72.
20. 横田伸一，堤裕幸，氷見徹夫．RSウイルス感染症に対するマクロライドの可能性．Jpn J Antibiot 2014; 67(3):147-155.
21. 横田伸一，今野武津子．ヘリコバクター・ピロリ感染症と鉄欠乏性貧血．臨床と微生物 2015; 42(2):165-170.
22. 小笠原徳子，横田伸一，山本圭祐，橋本真，堤裕幸，氷見徹夫．最新動向から見直す呼吸器感染症マネジメント ウイルス性呼吸器感染症―冬期のRSウイルス流行に備えて．感染と抗菌薬 2015; 18(3):242-246.
23. 氷見徹夫，高野賢一，山下恵司，小笠原徳子，山本圭佑，堤裕幸，小島隆，一宮慎吾，澤田典均，横田伸一．扁桃・アデノイドはなぜあるのか？鼻はなにをしているのか？―粘膜免疫・粘膜防御の最前線を探る．顎顔面口腔育成会誌 2015; 3(1):3-6.
24. 横田伸一．抗菌薬耐性菌の驚くべき進化と脅威．日本耳鼻咽喉科感染症・エアロゾル学会会誌 2016; 4(1):7-13.
25. 白石宗，横田伸一，吹谷智，横田篤．特集：乳酸菌が持つ新たな微生物機構の解明とその利用 リポテイコ酸の構造多様性から見える乳酸菌の特徴．JATAFFジャーナル 2017; 5(3):26-32.
26. 横田伸一，佐藤豊孝．抗菌薬多剤耐性におけるefflux pumpの役割を見直す．化学療法の領域 2017; 33(8):1698-1703.
27. 白石宗，久富亮佑，佐藤耶舞羽，森田直樹，吹谷智，佐藤豊孝，横田 篤，横田伸一．Lactobacillus gasseri に共通する種特異的なリポテイコ酸の化学構造． エンドトキシン・自然免疫研究 2018; 21: 35-37.
28. 大﨑敬子，横田憲治，林俊治，横田伸一，竹内啓晃，柴山恵吾，村鎌和成，加藤元嗣，杉山敏郎．Helicobacter pylori薬剤感受性試験の国内標準化に向けて―耐性菌基準パネルの作成―．日本ヘリコバクター学会誌 2022; 24(1): 44-48.
Book Chapter
1. Noguchi H, Yokota S, Ohtsuka H, Kohzuki T, Terashima M, Irie K. Broad-spectra human monoclonal antibodies that protect mice infected with Pseudomonas aeruginosa. In: Homma JY, Tanimoto H, Holder IA, Hoiby N, Doring G, eds.: Pseudomonas aeruginosa in human diseases: Antibiot. Chemother. vol. 44. Karger, Basel, 1991. pp. 172-184.
2. Yokota S, Amano K, Chiba S, Fujii N：Structures, biological activities and antigenic properties of Helicobacter pylori lipopolysaccharide. In: Pandalai SG ed.: Recent Research Developments in Microbiology vol. 7-Part I, Research Signpost, Kerala. 2003. pp. 251-267.
3. Tsutsumi H, Kojima T, Hirakawa S, Masaki T, Okabayashi T, Yokota S, Fujii N, Himi T, Sawada N. Respiratory syncytial virus infection and the tight junction of nasal epithelial cells. In Harabuchi Y ed.: Recent advances in tonsils and mucosal barriers of the upper airways. Adv. Otorhinolaryngol. Vol. 72. Karger, Basel, 2011. pp. 153-156.
4. Yokota S, Amano K, Fujii N：Helicobacter pylori lipopolysaccharide as a possible pathogenic factor for gastric carcinogenesis. In: Gastritis and Gastric Cancer-New Insights in Gastroprotection, Diagnosis and Treatments” (P. Tonino, ed.), InTech, Rijeka, 2011. pp.243-258,
1. 横田伸一，天野憲一，林俊治，久保田耐，藤井暢弘．ヘリコバクター・ピロリのリポ多糖のヒトにおける抗原性－胃癌由来株の低抗原性－．日本エンドトキシン研究会編．エンドトキシン研究１～基礎と臨床．菜根出版，東京，1998．pp. 113-121．
2. 天野憲一，柴田淑子，中島瑞穂，鈴木幸，横田伸一，林俊治，藤井暢弘：ヘリコバクター・ピロリLPSの構造と機能．エンドトキシン研究２～新しい展開（日本エンドトキシン研究会編）．菜根出版，東京，1999．pp. 105-112．
3. 藤井暢弘，木村浩一，林俊治，横田伸一，天野憲一：ポリメラーゼ連鎖反応法．Helicobacter pyloriと胃粘膜病変<最新の研究成果> 第2版（浅香正博編著）．先端医学社，東京，1999．pp174-178．
4. 横田伸一，天野憲一，Monteiro MA，藤井暢弘：ヘリコバクター・ピロリリポ多糖の多糖鎖部分の化学構造とエピトープ．エンドトキシン研究３～新しい局面（日本エンドトシン研究会編）．菜根出版，東京，2000．pp. 33-41．
5. 天野憲一，柴田淑子，横田伸一：低毒性ヘリコバクター・ピロリLPSの宿主との反応性-とくにLewis抗原を介した細菌と宿主のクロストーク-．エンドトキシン研究4～世界をリードするわが国の研究（日本エンドトキシン研究会編）．医学図書出版，東京，2001．pp. 103-109．
6. 清水俊明，横田伸一，藤井暢弘，塚本泰治：尿路上皮細胞の炎症反応における膜結合型CD14の重要性．エンドトキシン研究6－より深い理解をめざして－（日本エンドトキシン研究会編）．医学図書出版，東京，2003．pp.119-126．
7. 天野憲一，奥田真珠美，宮代英吉，横田伸一，藤井暢弘；Helicobacter pylori 感染によると思われるヒト疾患患者血清のLPSとの反応性．エンドトキシン研究7 －可能性を求めて－（日本エンドトキシン研究会編）．医学図書出版，東京，2004．pp.133-137．
8. 藤井暢弘，横田伸一：腸管出血性大腸菌O157感染症．道医シリーズ第45篇（生涯教育シリーズXVII）感染症－今、何が問題となっているのか？ （阿部庄作，塚本泰司監修）．北海道医師会，札幌，2007．pp.15-22．
9. 横田伸一，大西貴弘，室井正志，藤井暢弘，棚元憲一，天野憲一：低エンドトキシン活性を示すHelicobacter pylori リポ多糖の炎症反応惹起機構．エンドトキシン研究10－基礎と臨床の最新知見－（日本エンドトキシン研究会編）．医学図書出版，東京、2007．pp.15-23．
10. 横田伸一，岡林環樹，印藤智一，横沢紀子，藤井暢弘：麻疹ウイルス感染によるToll-like receptor情報伝達系の抑制とその意義．エンドトキシン研究10－基礎と臨床の最新知見－（日本エンドトキシン研究会編）．医学図書出版，東京，2007．pp.77-87．
11. 横田伸一，藤井暢弘：熱ショック蛋白質 (HSP) のToll-like リセプターアゴニスト作用と抗HSP自己抗体による増強作用．エンドトキシン研究11（日本エンドトキシン研究会編）．医学図書出版，東京，2007．pp.32-35．
12. 横田伸一，藤井暢弘，天野憲一：ヘリコバクター・ピロリのリポ多糖の発癌に関わる病原因子としての可能性．エンドトキシン研究12－自然免疫学の新たな展開－（日本エンドトキシン研究会編）．医学図書出版，東京，2009．pp.87-89．
13. 横田伸一，天野憲一，西谷千明，有木茂，黒木由夫，藤井暢弘：ピロリ菌リポ多糖の抗原性変化―サーファクタント蛋白質との相互作用と病原性との関連性―．エンドトキシン・自然免疫研究15－飛躍する自然免疫研究－（日本エンドトキシン・自然免疫研究会編）．医学図書出版，東京，2012．pp.1-6．
14. 白石宗，横田伸一，吹谷智，横田篤：腸内乳酸菌 Lactobacillus gasseri JCM 1131T のリポテイコ酸に認められた新奇構造．エンドトキシン・自然免疫研究18－自然免疫における生体防御ペプチドの多様性－（日本エンドトキシン・自然免疫研究会編）．医学図書出版，東京，2015．pp. 79-81．
15. 白石宗，佐藤耶舞羽，横田伸一，伊藤利章．吹谷智，横田篤．Lactobacillus gasseri JCM 1131Tの対数期におけるリポテイコ酸の局在：Membrane vesicle表層に露出されるリポテイコ酸．エンドトキシン・自然免疫研究19－新たなる基礎と臨床の架け橋－（日本エンドトキシン・自然免疫研究会編）．医学図書出版，東京，2016．pp. 15-17.
16. 白石宗，北川学，山本聡，久富亮佑，佐藤豊孝，涌井秀樹，伊藤英晃，宮本篤，横田伸一．納豆由来ペプチドの特異な殺菌効果とその作用機序．エンドトキシン・自然免疫研究20－自然免疫における化学生物学の貢献－（日本エンドトキシン・自然免疫研究会編）．医学図書出版，東京，2017．pp.39-42.
教科書等
1. 横田伸一．感染症と生体防御．みてわかる薬学 図解 微生物学・感染症・化学療法．（藤井暢弘，山本友子編）．南山堂，東京，2014．pp. 61-119．
2. 横田伸一．化学療法（抗菌薬）．みてわかる薬学 図解 微生物学・感染症・化学療法．（藤井暢弘，山本友子編）．南山堂，東京，2014．pp. 391-438．
3. 横田伸一．グラム陰性好気性桿菌．病原微生物学―基礎と臨床．（荒川宣親，柳雄介，神谷茂編）．東京化学同人，東京，2014．pp. 88-92．
4. 横田伸一．らせん菌群．シンプル微生物学（改訂第6版）．（小熊恵二，堀田博，若宮伸隆編）．南江堂，東京，2018. pp. 157-162．
5. 横田伸一．エンドトキシン（リポ多糖）．標準微生物学（第13版）．（中込治監修，神谷茂，錫谷達夫編）．医学書院，東京，2018. pp. 71-74．
6. 横田伸一．抗菌薬．エース薬理学．（金井好克監修，安西尚彦，安藤仁，浅井聰編）．南山堂，東京，2020. pp. 245-252.
7. ClinicalKey in Students Japan (CSK) （医学部向けeラーニングシステム） (Elsevier Japan, Tokyo, Japan) 微生物学
編集委員．
8. 病原体等安全取扱・管理指針（改訂版）. 日本細菌学会. 2023. 編集委員．